Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7605177B2 · kind B2 · utility
7Cited by
38References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2005 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Apr 14, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.